Dhan Chand: Collaboration and innovation in cancer treatment at SITC 2024
Dhan Chand, Vice President of Research at Agenus, posted on LinkedIn:
“Curing cancer requires more than innovative therapies – it demands the power of collaboration, fearless curiosity, diverse expertise and shared purpose.
Join me at Poster #720 at SITC 2024! I’ll share how botensilimab, our multi-functional Fc-enhanced anti-CTLA-4 antibody, combines with established and emerging therapies to drive effective anti-tumor immunity in hard-to-treat tumor models.
I am so proud of our extensive partnerships across academia and industry that are unlocking these promising treatment approaches for patients with limited treatment options.”
Dhan Chand, Ph.D., is Vice President of Research at Agenus, focusing on cancer immunology, immunotherapy, and cell and molecular biology. Previously, he served as a Graduate Research Assistant and Project Co-Leader in the Department of Cell and Systems Biology at the University of Toronto.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023